Next Article in Journal
Music-Based Therapeutic Interventions for People with Dementia: A Mini-Review
Previous Article in Journal
Effects of Shugan-Jianpi Recipe on the Expression of the p38 MAPK/NF-κB Signaling Pathway in the Hepatocytes of NAFLD Rats
Previous Article in Special Issue
Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
Article Menu
Issue 4 (December) cover image

Export Article

Open AccessFeature PaperReview
Medicines 2018, 5(4), 107;

New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders

Department of Biomedical Sciences, Division of Neuroscience and Clinical Pharmacology, University of Cagliari, 09042 Monserrato, Italy
Medication Development program, NIDA-IRP, NIH/DHHS, NIDA suite 3301, Baltimore, MD 21224, USA
Centre of Excellence “Neurobiology of Dependence”, University of Cagliari, 09042 Monserrato, Italy
CNR Institute of Neuroscience – Cagliari, National Research Council, 09042 Monserrato, Italy
National Institute of Neuroscience (INN), University of Cagliari, 09042 Monserrato, Italy
Author to whom correspondence should be addressed.
Received: 7 August 2018 / Revised: 26 September 2018 / Accepted: 30 September 2018 / Published: 2 October 2018
(This article belongs to the Special Issue Cannabinoids for Medical Use)
Full-Text   |   PDF [718 KB, uploaded 2 October 2018]   |  


Following the discovery of the endocannabinoid system and its potential as a therapeutic target for various pathological conditions, growing interest led researchers to investigate the role of cannabis and its derivatives for medical purposes. The compounds Δ9-tetrahydrocannabinol and cannabidiol are the most abundant phytocannabinoids found in cannabis extracts, as well as the most studied. The present review aims to provide an overview of the current evidence for their beneficial effects in treating psychiatric disorders, including schizophrenia, anxiety, and depression. Nevertheless, further investigations are required to clarify many pending issues, especially those relative to the assessment of benefits and risks when using cannabis for therapeutic purposes, thereby also helping national and federal jurisdictions to remain updated. View Full-Text
Keywords: phytocannabinoids; Δ9-tetrahydrocannabinol; cannabidiol; psychiatric disorders phytocannabinoids; Δ9-tetrahydrocannabinol; cannabidiol; psychiatric disorders

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Scherma, M.; Masia, P.; Deidda, M.; Fratta, W.; Tanda, G.; Fadda, P. New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders. Medicines 2018, 5, 107.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top